The £4 Drug That Scientists Think Could Slow Ageing

There is a drug that costs less than a cup of coffee per month, has been safely prescribed to hundreds of millions of people for six decades, and is currently being investigated as the most promising pharmaceutical intervention against human ageing ever trialled.

It is not a new compound developed by a Silicon Valley longevity startup. It is metformin — the first-line medication for type 2 diabetes, available as a generic drug at negligible cost in almost every country in the world.

The story of how metformin went from diabetes treatment to the centre of longevity science is one of the more interesting convergences in contemporary medicine — and the evidence, while still developing, is compelling enough to explain why a growing number of healthy people without diabetes are asking their doctors about it.

TL;DR

• Metformin has been safely used to treat type 2 diabetes since the 1950s. Epidemiological data consistently shows that people with diabetes on metformin live longer than people without diabetes not on metformin — a paradox that first attracted serious longevity research attention.
• The TAME (Targeting Aging with Metformin) trial — funded by the American Federation for Aging Research — is the world''s first clinical trial in which ageing itself is the therapeutic target. It is enrolling 3,000 adults aged 65 to 79 across 14 US research centres.
• Metformin activates AMPK, inhibits mTOR, reduces inflammation, stimulates autophagy, and produces epigenetic changes consistent with slowed biological ageing across multiple systems simultaneously.
• A July 2025 review in Cancers confirmed metformin''s ability to reduce cancer incidence, enhance immunotherapy outcomes, delay multimorbidity, and reverse biological age markers.
• A September 2024 primate study — 40 months, cynomolgus monkeys — found metformin reduced biological brain age by approximately 6 years and preserved cortical thickness and cognitive function.
• The significant concern: metformin blunts the muscle hypertrophy response to resistance training in older adults by inhibiting mTORC1. For people who exercise regularly, this is the most clinically important trade-off in the evidence.
• The 2025 MET-PREVENT trial in The Lancet Healthy Longevity found no significant improvements in mobility or physical function markers with metformin versus placebo in older adults with sarcopenia — a sobering result for the functional ageing case.

The paradox that started everything

The longevity story of metformin begins with an observation that should not have been possible.

People with type 2 diabetes have significantly higher rates of cardiovascular disease, cancer, kidney disease, and cognitive decline than the general population. They die, on average, years earlier. And yet, multiple large-scale studies in the early 2010s found that people with type 2 diabetes taking metformin were outliving people without diabetes who were not taking it.

Experts at Cardiff University pointed to evidence that human patients treated with metformin for diabetes live longer than expected — often longer than people without diabetes. This paradoxical finding — that a treatment for a life-shortening disease could extend lifespan beyond that of healthy untreated people — was the observation that launched a wave of longevity research.

The implication was straightforward: metformin might be doing something beyond glycaemic control. Something that affects the fundamental biology of ageing.

What metformin actually does: the mechanisms

Metformin''s effects on the biology of ageing operate through several interconnected pathways — which is partly why it is considered more promising than most single-target interventions.

AMPK activation

The primary mechanism through which metformin affects ageing biology is activation of AMP-activated protein kinase — AMPK. AMPK is the cell''s master energy sensor, activated when cellular energy is low. It shifts cells from energy-consuming anabolic processes toward energy-conserving catabolic ones — including autophagy, the cellular cleaning process that removes damaged proteins and organelles.

AMPK activation has consistently extended lifespan and healthspan in model organisms. It mimics some of the effects of caloric restriction — one of the most robust interventions for extending lifespan across species — without requiring dietary restriction.

mTOR inhibition

AMPK is an endogenous inhibitor of mTORC1 — the mammalian target of rapamycin complex 1. mTOR is a central regulator of cell growth, protein synthesis, and nutrient sensing. When it is chronically overactivated — as it tends to be in modern dietary conditions — it drives accelerated cellular ageing, reduced autophagy, and increased senescence.

Inhibiting mTOR is one of the most consistently lifespan-extending interventions across model organisms. Rapamycin — a direct mTOR inhibitor — extends lifespan in mice even when given late in life. Metformin achieves partial mTOR inhibition through AMPK activation, producing similar downstream effects with a considerably more established safety profile.

Inflammation reduction

Chronic low-grade inflammation — sometimes called inflammageing — is one of the primary drivers of age-related disease and decline. Metformin suppresses multiple inflammatory pathways, including NF-κB signalling, and reduces circulating inflammatory markers including IL-6, TNF-α, and CRP.

A July 2025 review in Cancers described metformin as affecting several core biological pathways involved in ageing, cancer progression, and immune regulation — including metabolic processes, inflammation, gut microbiota composition, and gene expression. Clinical data now demonstrate its ability to reduce cancer incidence, enhance immunotherapy outcomes, delay multimorbidity, and reverse biological age markers.

Epigenetic effects

Perhaps the most striking recent evidence is metformin''s effects on biological age as measured by epigenetic clocks — methylation-based measures of biological rather than chronological ageing.

A September 2024 primate study — 40 months in cynomolgus monkeys given metformin at 20mg/kg/day — found a reduction of approximately 6 years in biological brain age based on DNA methylation clocks, alongside preserved cortical thickness particularly in the frontal lobe, and improved short-term memory and cognitive flexibility.

Epigenetic clock studies in humans are less definitive but consistent with the primate findings — metformin use is associated with younger biological age relative to chronological age in observational studies.

Gut microbiome modulation

An increasingly recognised mechanism involves the gut microbiome. Metformin significantly alters gut microbiota composition, increasing the abundance of certain beneficial species and reducing pathogenic ones. The gut microbiome mediates some of metformin''s metabolic effects — studies transplanting the microbiomes of metformin-treated animals into untreated ones have shown partial transfer of metformin''s metabolic benefits. This may be one of the pathways through which metformin produces systemic effects beyond its direct cellular mechanisms — and why interventions like the Gut Reset matter as a foundation regardless of whether anyone ever takes the drug.

The TAME trial: testing ageing as a therapeutic target

The Targeting Aging with Metformin trial is, in concept, one of the most significant clinical trials in the history of medicine — because it is the first trial in which ageing itself, rather than a specific age-related disease, is the therapeutic target.

The trial is enrolling 3,000 adults aged 65 to 79 across 14 research centres in the United States. Participants are people who already have one or two age-related conditions — cancer, cardiovascular disease, or cognitive impairment — but not all three. The primary endpoint is the development of a composite of new age-related diseases — the hypothesis being that metformin will delay the onset of the next condition rather than targeting any single disease.

Randomising the indication to ageing itself required significant negotiations with the FDA, which does not currently recognise ageing as a disease. Since ageing per se is not recognised as a disease, researchers began discussions with the FDA to hammer out study specifics — and succeeded in establishing cancer, cardiovascular disease, and cognitive decline as measurable clinical endpoints through which the effect of slowing ageing could be assessed.

The trial is not yet complete. Full results are anticipated in the coming years. But the Mendelian randomisation study using UK Biobank data — which used genetic variants to simulate metformin''s effects on ageing biomarkers — found metformin could have potential benefits for healthy ageing and might foreshadow results from the TAME trial, serving as a proof of concept that metformin targets the biology of ageing.

The cancer evidence

The cancer findings are among the most clinically consequential in the metformin longevity literature — and among the most robust.

Multiple observational studies and meta-analyses have found that people taking metformin have lower rates of several cancers compared to people on other diabetes medications or no diabetes medication. The July 2025 Cancers review confirmed metformin''s ability to reduce cancer incidence and enhance immunotherapy outcomes — a newer and particularly interesting finding that metformin may improve the effectiveness of immunotherapy drugs used to treat established cancers.

The mechanism involves metformin''s effects on cancer cell metabolism — cancer cells are highly dependent on glucose and lactate, and metformin''s disruption of mitochondrial energy production selectively disadvantages cells with high metabolic demands. It also reduces insulin and IGF-1 levels, which drive cancer cell proliferation.

The cancer-protective effect is most clearly established for endometrial, colorectal, breast, and pancreatic cancers. It is observed consistently enough across different study types and populations to be taken seriously — though it remains observational rather than proven in randomised cancer prevention trials.

The significant concern: exercise interference

This is the finding that most complicates the longevity case for metformin in people who exercise — and it is one the field has not yet satisfactorily resolved.

Metformin blunts the muscle hypertrophy response to resistance training in older adults. The MASTERS trial — a randomised, double-blind, placebo-controlled trial in 94 healthy adults over 65 — found that people taking metformin gained significantly less lean body mass, thigh muscle mass, and thigh muscle area after 14 weeks of supervised resistance training than those taking placebo.

The mechanism is the same as the longevity mechanism. Metformin activates AMPK and inhibits mTORC1. But mTORC1 is also a key regulator of muscle growth — it is the primary intracellular signal through which resistance training stimulates muscle protein synthesis. By inhibiting mTORC1, metformin prevents the muscle-building adaptation that resistance training is supposed to produce.

The reason metformin dampens exercise benefits is still being investigated. Metformin partly works by inhibiting specific mitochondrial processes — the same interference that reduces oxidative stress and regulates blood sugar may also block the cellular changes triggered by exercise, including better mitochondrial efficiency and improved aerobic performance.

This creates a genuine dilemma for the longevity case. The two most robustly evidence-based interventions for healthy ageing are exercise — particularly resistance training — and, potentially, metformin. But they may work against each other in the muscle at a mechanistic level. Regular, consistent resistance exercise is irreplaceable for preserving muscle mass, strength, and metabolic function in ageing. If metformin partially negates this — as the MASTERS trial suggests it does — the net longevity benefit is not straightforward.

The MET-PREVENT disappointment

The 2025 MET-PREVENT trial — published in The Lancet Healthy Longevity — is the most recent and sobering piece of evidence in the metformin longevity picture.

It was a double-blind randomised trial in older adults with sarcopenia and pre-frailty — exactly the population that might most benefit from metformin''s anti-ageing mechanisms. It found no significant improvements in mobility or physical function markers with metformin versus placebo.

This does not negate the molecular and epidemiological evidence. But it does confirm that metformin modifying molecular pathways related to ageing does not yet translate into measurable functional improvements in healthy older people. The gap between biological mechanism and clinical outcome is the central uncertainty in the entire metformin longevity story.

Who might benefit — and who should be cautious

The honest current position is that the evidence does not yet support healthy people without diabetes taking metformin for longevity — not because the evidence is against it, but because it is not yet strong enough to justify it.

The TAME trial, when complete, will provide the most definitive answer available. Until then, the people for whom the evidence most clearly supports metformin use are:

• People with type 2 diabetes or prediabetes — where the combination of glycaemic benefit, cardiovascular protection, and potential longevity effects makes metformin the most comprehensively evidence-backed first-line treatment.
• People with metabolic syndrome — where metformin''s insulin-sensitising, anti-inflammatory, and metabolic effects address multiple risk factors simultaneously.
• People at high cancer risk — where the observational cancer-protective evidence is sufficient to at least include metformin in discussions with an oncologist or GP.

For people who exercise regularly and prioritise muscle health — the MASTERS trial findings are a genuine caution. Anyone considering metformin for longevity who also does regular resistance training should discuss the exercise interference evidence with their doctor before starting. The same applies to anyone whose stress, sleep or recovery is already compromised — the fundamentals covered in the Sleep Reset and Stress Reset matter more for healthspan than any pharmaceutical add-on.

FAQs

What is metformin used for?

Metformin is the world''s most widely prescribed medication for type 2 diabetes. It works primarily by reducing the liver''s output of glucose, improving insulin sensitivity, and through multiple other mechanisms that have made it the standard first-line treatment for type 2 diabetes for over 60 years. It is available as a generic drug at very low cost.

Can metformin slow ageing?

The evidence is promising but not yet definitive for healthy people. Metformin activates biological pathways — AMPK activation, mTOR inhibition, inflammation reduction, autophagy stimulation — that consistently extend healthspan in animal models. Observational studies in humans find metformin users outliving comparable non-users. Epigenetic clock studies show younger biological age in metformin users. The TAME trial is testing this directly in humans — full results are anticipated in the coming years. The 2025 MET-PREVENT trial found no significant functional improvements in older adults with sarcopenia, which is a sobering counterpoint.

What is the TAME trial?

The Targeting Aging with Metformin trial is the world''s first clinical trial in which ageing itself — rather than a specific disease — is the therapeutic target. It is enrolling 3,000 adults aged 65 to 79 across 14 US research centres, with a primary endpoint of delayed onset of new age-related diseases including cancer, cardiovascular disease, and cognitive impairment. It represents a landmark shift in how medicine conceptualises ageing — from an inevitable background process to a modifiable therapeutic target.

Does metformin interfere with exercise?

This is the most clinically important concern for people considering metformin for longevity. The MASTERS trial — a randomised controlled trial in adults over 65 — found that metformin significantly blunted gains in lean body mass and muscle mass from resistance training compared to placebo. The mechanism involves metformin''s inhibition of mTORC1 — the same pathway through which resistance training stimulates muscle growth. For people who exercise regularly and prioritise muscle health, this is a genuine trade-off that warrants discussion with a doctor before considering metformin for longevity purposes.

Should I take metformin for longevity if I don''t have diabetes?

The evidence does not yet support this for healthy people without diabetes or metabolic risk factors. The TAME trial will provide the most definitive answer. Until then, the biological evidence is promising but not sufficient to justify off-label use for longevity in healthy individuals — particularly given the exercise interference concern. The exception may be people with prediabetes or metabolic syndrome, where metformin has established benefits that overlap with its potential longevity effects.

Is metformin safe?

Metformin has one of the best-established safety profiles of any drug in clinical use. It has been prescribed to hundreds of millions of people for over 60 years. The most common side effects are gastrointestinal — nausea, diarrhoea, stomach discomfort — which are reduced by starting at a low dose and taking it with food. It can deplete vitamin B12 with long-term use, which warrants monitoring and supplementation if needed. It is contraindicated in severe kidney disease. It is not appropriate for people with significant hepatic impairment.

The bottom line

Metformin is the most interesting pharmaceutical candidate in longevity research — not because it is new or exotic, but because it is cheap, safe, familiar, and produces effects on the fundamental biology of ageing through multiple overlapping mechanisms simultaneously.

The epidemiological signal is striking. The mechanistic evidence is compelling. The primate data is the most encouraging animal study in the field. And the TAME trial — when it reports — will either transform medicine''s approach to ageing or significantly temper the excitement.

What the evidence does not yet support is healthy people without diabetes taking metformin for longevity without medical supervision and without a clear understanding of the exercise trade-off. The muscle interference finding is real and clinically significant. The MET-PREVENT disappointment is a reminder that biological mechanisms do not always translate into the functional outcomes that matter most.

The honest framing: this is one of the most promising leads in longevity medicine, at an advanced enough stage to watch very closely — but not yet at a stage where the evidence supports acting on without medical guidance.

For the lifestyle foundations that support healthy ageing most comprehensively — sleep, movement, nutrition, stress management — the Reset Series™ from Vitae provides structured, evidence-based protocols, including the Sleep Reset, Stress Reset and Gut Reset. They pair naturally with the Reset Companion for tailored daily support — covering the foundational behaviours that any longevity intervention, pharmaceutical or otherwise, ultimately depends on.

Related reading: GLP-1 Drugs Are Doing Far More Than Anyone Expected · Body Fat Depots Explained: Why Where You Store Fat Matters More Than How Much · Understanding MASLD — and How to Support a Healthier Liver.

Popular Articles